Free Trial Information
BioCentury | Oct 15, 2020
Product Development

Lingering questions as Vertex sheds $15B after Phase II setback

...the stellar launch of Vertex’s flagship Trikafta elexacaftor/tezacaftor/ivacaftor...
Read More
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...transformed the CF treatment landscape in recent years. Those, including Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor and Trikafta elexacaftor/tezacaftor/ivacaftor...
Read More
BioCentury | Aug 25, 2020
Deals

Reverse merger offers Yumanity faster, less risky path to NASDAQ

...did not measure up to Vertex’s Trikafta elexacaftor/tezacaftor/ivacaftor...
Read More
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

...CF combo meets in postapproval study Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said cystic fibrosis therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
...vanilloid 1 BioCentury Staff voclosporin (LX211, luveniq, ISA247, ISATX247, trans-ISA247, Voclera) JZP-258 Qutenza, capsaicin (NGX-4010, Transacin) Ryoncil (remestemcel-L) elafibranor (GFT505) Trikafta, elexacaftor/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) liso-cel...
Read More
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

...very cheaply.” David Borah, GW&K An example is the cystic fibrosis (CF) combination therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
Read More
BioCentury | Jun 30, 2020
Product Development

Vertex, NHS in deal to make CF triplet available in England once EC approves

...Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and NHS that had provided access to Orkambi lumacaftor/ivacaftor and Symkevi tezacaftor/ivacaftor...
...England. Under the new arrangement, CF patients in England will have immediate access to Kaftrio elexacaftor/tezacaftor/ivacaftor...
...Trials Landscape” ). Targets CFTR - Cystic fibrosis transmembrane conductance regulator Stephen Hansen, Associate Editor Trikafta, elexacaftor/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) Vertex...
Read More
BioCentury | Jun 26, 2020
Regulation

Data Bytes: CHMP’s June opinions

...certain adults with transfusion-dependent anemia. Elizabeth S. Eaton, Staff Writer Veklury, remdesivir (GS-5734) Reblozyl, luspatercept-aamt (ACE-536) IdeS, imlifidase Trikafta, elexacaftor/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) Turalio...
Read More
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), which includes Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor, Symdeko tezacaftor/ivacaftor and Trikafta elexacaftor/tezacaftor/ivacaftor...
Read More
BioCentury | Apr 30, 2020
Finance

April 29 Quick Takes: After ADC approval, Immunomedics raises $420M for rollout; plus Genespire, Vertex, Ocumension and Cadent

...billion, after the company reported a year-over-year sales increase of 77%. Cystic fibrosis therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
Read More
BioCentury | Apr 4, 2020
Finance

Investors are seeking only one thing: a sign the pandemic tide is shifting

...instance, Craig said there’s little worry about the launch of new cystic fibrosis therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
Read More
Items per page:
1 - 10 of 157